Media & news

The Extraordinary General Meeting of Nobel Biocare approves all proposals of the Board of Directors

Following the settlement of the public tender offer of Danaher Corporation on December 11, 2014, Nobel Biocare Holding AG’s Extraordinary General Meeting today endorsed all proposals put forward by the Board of Directors.

The new Board of Directors consists of Colin Davis, Jonathan P. Graham and Mischa Reis as Members and Philip Bernard Whitehead as Member and Chairman. All members have been elected for a term until the next Annual General Meeting.

The new Board of Directors resolved in his first meeting to move the date for the publication of the full year results to April 28, 2015 and the date of the next ordinary Annual General Meeting to June 29, 2015. Furthermore, Nobel Biocare Holding AG will no longer publish quarterly results.

Contact information:

Süha Demokan

Investor & Corporate Relations

Tel: +41 43 211 42 30, +41 79 430 81 46

suha.demokan@nobelbiocare.com

Nobel Biocare is a world leader in the field of innovative implant-based dental restorations. The company’s portfolio offers solutions from single tooth to fully edentulous indications with dental implant systems (including key brands NobelActive®, Brånemark System® and NobelReplace®), a comprehensive range of high-precision individualized prosthetics and CAD/CAM systems (NobelProcera®), diagnostics, treatment planning and guided surgery solutions (NobelClinician® and DTX Studio™) and biomaterials (creos). Nobel Biocare supports its customers through all phases of professional development, offering world-class training and education along with practice support and patient information materials. The company is headquartered in Zurich, Switzerland. Production takes place at six sites located in the United States, Sweden, Japan and Israel. Products and services are available in over 80 countries through subsidiaries and distributors.